FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952690147> ?p ?o ?g. }

• W2952690147 endingPage "25" @default.
• W2952690147 startingPage "24" @default.
• W2952690147 abstract "Background: VTd is a standard of care for transplant-eligible newly diagnosed multiple myeloma (NDMM) patients. Daratumumab (DARA), a CD38 mAb, significantly reduced the risk of progression or death and improved complete response (CR) and minimal residual disease (MRD)-negative rates in relapsed refractory multiple myeloma or transplant-ineligible NDMM in phase 3 studies. Aims: We report the primary and final analysis of Part 1 of the CASSIOPEIA trial for NDMM. Methods: In Part 1, transplant-eligible NDMM patients 18–65 years old were randomized 1:1 to VTd (6 28-day cycles [C; 4 pre-autologous stem cell transplantation {ASCT} induction, 2 post-ASCT consolidation] of V 1.3 mg/m2 SC BIW Week [W] 1–2; T 100 mg PO QD; d 40–80 mg/week PO or IV W 1-4 C 1-2, W 1-3 C 3-6) ± DARA (16 mg/kg IV QW C 1-2, Q2W C 3-6). Melphalan 200 mg/m2 was pre-ASCT therapy. The primary endpoint was the rate of post-consolidation stringent complete response (sCR) assessed at Day 100 post-ASCT. Part 2 (maintenance) is ongoing. Results: A cohort of 1085 patients (D-VTd, 543; VTd, 542) was randomized. The Day 100 post-ASCT sCR rate was significantly higher for the D-VTd arm versus the VTd arm (28.9% vs 20.3%; P = 0.0010; Table). With 18.8-months median follow-up, progression-free survival (PFS) from first randomization favored D-VTd with a hazard ratio (HR) of 0.47 (95% CI, 0.33-0.67; P < 0.0001; Figure). With median PFS not reached in either arm, 18-month PFS rates were 92.7% versus 84.6% for D-VTd versus VTd. Rates of ≥CR, ≥VGPR, and MRD negativity supported sCR results (Table). Overall survival is immature with 46 deaths on study (D-VTd, 14; VTd, 32; HR, 0.43; 95% CI, 0.23–0.80). The most common (≥10%) grade 3/4 treatment-emergent adverse events (D-VTd/VTd) were neutropenia (27.6%/14.7%), lymphopenia (17.0%/9.7%), stomatitis (12.7%/16.4%), and thrombocytopenia (11.0%/7.4%). In the D-VTd arm, infusion-related reactions occurred in 35.4% of patients.Summary/Conclusion: D-VTd in induction prior to and consolidation after ASCT improved depth of response (sCR, ≥CR, and MRD negativity) and PFS with acceptable safety. The favorable benefit-risk profile supports the use of D-VTd in transplant-eligible NDMM. CASSIOPEIA is the first study to demonstrate the clinical benefit of daratumumab plus standard of care in transplant-eligible NDMM patients." @default.
• W2952690147 created "2019-06-27" @default.
• W2952690147 creator A5000761302 @default.
• W2952690147 creator A5002972322 @default.
• W2952690147 creator A5004217461 @default.
• W2952690147 creator A5005665639 @default.
• W2952690147 creator A5006799794 @default.
• W2952690147 creator A5013519562 @default.
• W2952690147 creator A5015113939 @default.
• W2952690147 creator A5015647468 @default.
• W2952690147 creator A5016941619 @default.
• W2952690147 creator A5020056942 @default.
• W2952690147 creator A5020665054 @default.
• W2952690147 creator A5021139263 @default.
• W2952690147 creator A5023937847 @default.
• W2952690147 creator A5025438493 @default.
• W2952690147 creator A5025996929 @default.
• W2952690147 creator A5026970655 @default.
• W2952690147 creator A5030565933 @default.
• W2952690147 creator A5035919558 @default.
• W2952690147 creator A5037068433 @default.
• W2952690147 creator A5038795221 @default.
• W2952690147 creator A5038965613 @default.
• W2952690147 creator A5043695215 @default.
• W2952690147 creator A5044238802 @default.
• W2952690147 creator A5045605051 @default.
• W2952690147 creator A5045640174 @default.
• W2952690147 creator A5045881972 @default.
• W2952690147 creator A5047262318 @default.
• W2952690147 creator A5047625349 @default.
• W2952690147 creator A5048560248 @default.
• W2952690147 creator A5052003991 @default.
• W2952690147 creator A5053469869 @default.
• W2952690147 creator A5054678607 @default.
• W2952690147 creator A5056620433 @default.
• W2952690147 creator A5056762112 @default.
• W2952690147 creator A5058940187 @default.
• W2952690147 creator A5060698923 @default.
• W2952690147 creator A5063422967 @default.
• W2952690147 creator A5064748195 @default.
• W2952690147 creator A5066247828 @default.
• W2952690147 creator A5068303471 @default.
• W2952690147 creator A5068940705 @default.
• W2952690147 creator A5069447323 @default.
• W2952690147 creator A5069449708 @default.
• W2952690147 creator A5071589084 @default.
• W2952690147 creator A5073015935 @default.
• W2952690147 creator A5075610619 @default.
• W2952690147 creator A5075950291 @default.
• W2952690147 creator A5077388722 @default.
• W2952690147 creator A5080134364 @default.
• W2952690147 creator A5082698003 @default.
• W2952690147 creator A5083283511 @default.
• W2952690147 creator A5083385949 @default.
• W2952690147 creator A5086077649 @default.
• W2952690147 creator A5087052731 @default.
• W2952690147 creator A5087353636 @default.
• W2952690147 creator A5089853890 @default.
• W2952690147 date "2019-06-01" @default.
• W2952690147 modified "2023-10-01" @default.
• W2952690147 title "S145 PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS" @default.
• W2952690147 doi "https://doi.org/10.1097/01.hs9.0000558800.37954.72" @default.
• W2952690147 hasPublicationYear "2019" @default.
• W2952690147 type Work @default.
• W2952690147 sameAs 2952690147 @default.
• W2952690147 citedByCount "1" @default.
• W2952690147 countsByYear W29526901472019 @default.
• W2952690147 crossrefType "journal-article" @default.
• W2952690147 hasAuthorship W2952690147A5000761302 @default.
• W2952690147 hasAuthorship W2952690147A5002972322 @default.
• W2952690147 hasAuthorship W2952690147A5004217461 @default.
• W2952690147 hasAuthorship W2952690147A5005665639 @default.
• W2952690147 hasAuthorship W2952690147A5006799794 @default.
• W2952690147 hasAuthorship W2952690147A5013519562 @default.
• W2952690147 hasAuthorship W2952690147A5015113939 @default.
• W2952690147 hasAuthorship W2952690147A5015647468 @default.
• W2952690147 hasAuthorship W2952690147A5016941619 @default.
• W2952690147 hasAuthorship W2952690147A5020056942 @default.
• W2952690147 hasAuthorship W2952690147A5020665054 @default.
• W2952690147 hasAuthorship W2952690147A5021139263 @default.
• W2952690147 hasAuthorship W2952690147A5023937847 @default.
• W2952690147 hasAuthorship W2952690147A5025438493 @default.
• W2952690147 hasAuthorship W2952690147A5025996929 @default.
• W2952690147 hasAuthorship W2952690147A5026970655 @default.
• W2952690147 hasAuthorship W2952690147A5030565933 @default.
• W2952690147 hasAuthorship W2952690147A5035919558 @default.
• W2952690147 hasAuthorship W2952690147A5037068433 @default.
• W2952690147 hasAuthorship W2952690147A5038795221 @default.
• W2952690147 hasAuthorship W2952690147A5038965613 @default.
• W2952690147 hasAuthorship W2952690147A5043695215 @default.
• W2952690147 hasAuthorship W2952690147A5044238802 @default.
• W2952690147 hasAuthorship W2952690147A5045605051 @default.
• W2952690147 hasAuthorship W2952690147A5045640174 @default.
• W2952690147 hasAuthorship W2952690147A5045881972 @default.
• W2952690147 hasAuthorship W2952690147A5047262318 @default.
• W2952690147 hasAuthorship W2952690147A5047625349 @default.
• W2952690147 hasAuthorship W2952690147A5048560248 @default.
• W2952690147 hasAuthorship W2952690147A5052003991 @default.

• next